Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

452.17 +0.44 (+0.10%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Here's How Much $1000 Invested In Alnylam Pharmaceuticals 10 Years Ago Would Be Worth Today
 
Via Benzinga
$1000 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
 
Via Benzinga
Where Alnylam Pharmaceuticals Stands With Analysts
 
Via Benzinga
A Closer Look at Alnylam Pharmaceuticals's Options Market Dynamics
 
Via Benzinga
How Is The Market Feeling About Alnylam Pharmaceuticals?
 
Via Benzinga
Here's How Much $100 Invested In Alnylam Pharmaceuticals 10 Years Ago Would Be Worth Today
 
Via Benzinga
Earnings Scheduled For July 31, 2025
 
Via Benzinga
Where Alnylam Pharmaceuticals Stands With Analysts
 
Via Benzinga
If You Invested $1000 In This Stock 15 Years Ago, You Would Have This Much Today
 
Via Benzinga
Demystifying Alnylam Pharmaceuticals: Insights From 19 Analyst Reviews
 
Via Benzinga
This Alnylam Pharmaceuticals Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday
 
Via Benzinga
Reddit, Wingstop, And Generac Are Among Top 10 Large Cap Gainers Last Week (July 28-August 1): Are The Others In Your Portfolio?
Reddit, Wingstop, and Generac led large-cap gains last week on strong Q2 results and upbeat guidance across multiple sectors. 
Via Benzinga
Alnylam's Amvuttra Makes Powerful Entrance, Eyes First-Line Dominance
Alnylam sees strong Amvuttra uptake in ATTR-CM with $150 million revenue boost; analysts hike price targets following FDA approval and launch momentum. 
Via Benzinga
Alnylam Pharmaceuticals Q2 Earnings Crush Estimates, Stock Hits 52-Week High On Upbeat Forecast
Alnylam stock jumps after Q2 earnings beat and higher 2025 guidance, led by Amvuttra's rapid uptake and strong growth across the TTR and Rare franchises. 
Via Benzinga
Topics Earnings
Roblox, Carvana, eBay, C.H. Robinson Worldwide, Huntington Ingalls Industries And Other Big Stocks Moving Higher On Thursday
 
Via Benzinga
Here's How Much $100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth Today
 
Via Benzinga
This Target Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday
 
Via Benzinga
This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
 
Via Benzinga
A Glimpse Into The Expert Outlook On Alnylam Pharmaceuticals Through 10 Analysts
 
Via Benzinga
Alnylam Pharma Stock Outlook: Is ALNY Topping Out?
Alnylam Pharma Stock Outlook: For new entrants, chasing the momentum at this point would offer poor risk-reward dynamics. 
Via Benzinga
A Glimpse Into The Expert Outlook On Alnylam Pharmaceuticals Through 9 Analysts
 
Via Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
 
Via Benzinga
Tesla To Rally Around 45%? Here Are 10 Top Analyst Forecasts For Thursday
 
Via Benzinga
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 20 Years
 
Via Benzinga
What 18 Analyst Ratings Have To Say About Alnylam Pharmaceuticals
 
Via Benzinga
Moderna Beats Alnylam Appeal In COVID Vaccine Patent Case
The Federal Circuit upheld a ruling that Moderna's COVID-19 vaccine does not infringe Alnylam's mRNA patents related to the SM-102 lipid used in Spikevax. 
Via Benzinga
Topics Intellectual Property
Here's How Much $1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth Today
Via Benzinga
3 High-Flying Stocks That Could Soar Even More
Via The Motley Fool
$100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
 
Via Benzinga
Alnylam Delivers Q1 Surprise, Analysts Highlight Amvuttra Momentum, Limited Tariff Risk
Alnylam analysts highlight Amvuttra's strong launch positioning and limited tariff risk, with bullish ratings maintained despite early launch volatility. 
Via Benzinga
Topics World Trade
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.